Buparlisib (BKM120)

For research use only. Not for use in humans.

目录号:S2247 别名: NVP-BKM120 中文名称:布帕尼西

Buparlisib (BKM120) Chemical Structure

CAS No. 944396-07-0

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γIC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Buparlisib 可诱导凋亡。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2227.95 现货
RMB 1400.12 现货
RMB 2607.65 现货
RMB 7928.28 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Buparlisib (BKM120)发表文献178篇:

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γIC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Buparlisib 可诱导凋亡。Phase 2。
特性 BKM120是可用于口服的生物有效的PI3K抑制剂。
靶点
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
体外研究

BKM120作用于解除PI3K调节的细胞系,包括A2780, U87MG, MCF7和DU145时,具有抗增殖活性,GI50为0.1-0.7 nM。[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡,导致G1期细胞增多,S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡,且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。[2]BKM120作用于人类胃癌细胞系,降低mTOR下游信号,具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系,可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞,诱导凋亡,具有协同效应,但是作用于KRAS野生型细胞没有这种效果。[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M3XNbGN6fG:2b4jpZ{BCe3OjeR?= NGT0RVQ4OiCq NH3UO3ZFVVOR NYPO[mpYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCneIDy[ZN{cW6pIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQhf2m2aDDHTVUxKG:oIECuNFAxOTV6IN88US=> MXKyOFkxODJ4Nh?=
DU145 NHf4cXhEgXSxdH;4bYMhSXO|YYm= NGXxWJY4OiCq NUToR3Y1TE2VTx?= MofpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yCOS1KxJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMEC0N|Uh|ryP MYOyOFkxODJ4Nh?=
A2780 NWjYZYE3S3m2b4TvfIlkKEG|c3H5 NX\B[oJWPzJiaB?= M4nR[2ROW09? NEnOXHZEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3OzVizszN NXHNbmZOOjR7MECyOlY>
U87MG MlfYR5l1d3SxeHnjJGF{e2G7 NIHVU2w4OiCq MUDEUXNQ MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCXOEfNS{Bk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2PVgh|ryP Mn3GNlQ6ODB{Nk[=
A2780 M3nXTGZ2dmO2aX;uJGF{e2G7 MnK4NUBp NGLHRlJFVVOR MYjJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEW1JO69VQ>? NVjvOVVtOjR7MECyOlY>
DU145 NHz0fYFHfW6ldHnvckBCe3OjeR?= Mn\ZNUBp MY\EUXNQ MkPqTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1? NHnFS|czPDlyMEK2Oi=>
A2780 NVOyUG1CTnWwY4Tpc44hSXO|YYm= NU[xW2p[OSCq NGD4VVZFVVOR M{L3SmlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO|Qh|ryP NFWye44zPDlyMEK2Oi=>
MCF7 NYCwO2ZlTnWwY4Tpc44hSXO|YYm= NIqzOVIyKGh? MoHNSG1UVw>? MYLJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCHNUS1T{BufXSjboStcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMTFOwG0> MnPENlQ6ODB{Nk[=
U87MG M3HuSWZ2dmO2aX;uJGF{e2G7 M1SwW|EhcA>? Ml\nSG1UVw>? M3fZOWlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFXDOVAhd2ZiMD6xN{DPxE1? NV71dnl[OjR7MECyOlY>
A2780 NFnacWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGwVZo4OiCq M3L1dGROW09? NHfmcnhGSzVyPUCuOVIh|ryP MVqyOFkxODJ4Nh?=
SKMES-1 MVXDfZRwfG:6aXOgRZN{[Xl? M1LGdFEh|ryP M{HMR|czKGh? MXvJcoR2[2W|IHPlcIwh\GWjdHi= M{PY[VI3ODF|M{G4
H596 M2KwU2Z2dmO2aX;uJGF{e2G7 MonKNUDPxE1? MYrJcZBicXK|IHPlcIwhdWmpcnH0bY9v MUKyOlAyOzNzOB?=
HCC2450 Ml[2SpVv[3Srb36gRZN{[Xl? Mli2NUDPxE1? MYTJcZBicXK|IHPlcIwhcW64YYPpc44> MlrwNlYxOTN|MUi=
A549 M{TNOGZ2dmO2aX;uJGF{e2G7 MnT0OVAxKG6P MXe0PEBp Ml7aSG1UVw>? MUDJcohq[mm2czDBb5Qh[WO2aY\heIlwdg>? NFTpVo4zPTl|N{K5PS=>
A549 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDWNUDPxE1? MWW3NkBp MnzvSG1UVw>? MnLUTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MVOyOVk{PzJ7OR?=
H522 NFfa[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnvUGEyKM7:TR?= MXe3NkBp Mn\kSG1UVw>? Mmi1TY5pcWKrdIOgZ4VtdCCpcn;3eIg> NGOxTVUzPTl|N{K5PS=>
LNCaP M3;aXWZ2dmO2aX;uJGF{e2G7 NUjTXFFMOSEQvF2= NWDUc4Z[W3WycILld5NmeyCyLVHLWEBt\X[nbIO= M4jGfVI2OzZyN{m5
LNCaP95 MmL2SpVv[3Srb36gRZN{[Xl? MmnMNUDPxE1? M1rGb3N2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy| MXWyOVM3ODd7OR?=
HCT-15 NH6zc3dCeG:2b4Ppd{BCe3OjeR?= NEfuN3AyOCEQvF2= MmfCOFghcA>? MWfEUXNQ Mk\0TY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUG1JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NHjFRWYzPTF3MkK0OS=>
HCT-116 NFzIVItCeG:2b4Ppd{BCe3OjeR?= MVyxNEDPxE1? NFPNfXM1QCCq M1PM[2ROW09? M4L5W2lv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xNVYh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M3voSlI2OTV{MkS1
NCI-H460 NH3pdndCeG:2b4Ppd{BCe3OjeR?= MmfXNVAh|ryP MkLUOFghcA>? Mmf4SG1UVw>? NGjmdZVKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCQQ1mtTFQ3OCClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S|cH;0JI12fGG2aX;u MmHXNlUyPTJ{NEW=
SKOV-3 MYfBdI91d3OrczDBd5NigQ>? MWGxNEDPxE1? MoPaOFghcA>? MnuzSG1UVw>? NXHFSGlKUW6mdXPld{BieG:ydH;zbZMhcW5iU1vPWk0{KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= MV[yOVE2OjJ2NR?=
BSY-1 NVrtbVJ2SXCxdH;zbZMhSXO|YYm= NV6zPWR6OTBizszN M3XwblQ5KGh? NYGx[45FTE2VTx?= M4Trd2lv\HWlZYOgZZBweHSxc3nzJIlvKEKVWT2xJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MnzZNlUyPTJ{NEW=
MKN-1 NUfxTZBISXCxdH;zbZMhSXO|YYm= NFXsfG4yOCEQvF2= MUK0PEBp M1KzOmROW09? M{TWZ2lv\HWlZYOgZZBweHSxc3nzJIlvKE2NTj2xJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MoPPNlUyPTJ{NEW=
NCI-H522 NXPPc5JSSXCxdH;zbZMhSXO|YYm= NEf5OnMyOCEQvF2= MVe0PEBp MWHEUXNQ NYfHdWxZUW6mdXPld{BieG:ydH;zbZM> MUWyOVE2OjJ2NR?=
OVCAR-3 MV3BdI91d3OrczDBd5NigQ>? MkjUNVAh|ryP NXz6fWNZPDhiaB?= MYDEUXNQ NXP2R5BjUW6mdXPld{BieG:ydH;zbZM> MXiyOVE2OjJ2NR?=
HBC-5 MXXBdI91d3OrczDBd5NigQ>? M3vNV|ExKM7:TR?= NWfWcHd5PDhiaB?= NXjYWpRXTE2VTx?= MVfJcoR2[2W|IHHwc5B1d3Orcx?= MlPSNlUyPTJ{NEW=
RXF-631L MoHTRZBwfG:|aYOgRZN{[Xl? MlzRNVAh|ryP MV:0PEBp M3uxd2ROW09? M{TXOGlv\HWlZYOgZZBweHSxc3nz M3LjNVI2OTV{MkS1
MKN-45 NX7QXIYxSXCxdH;zbZMhSXO|YYm= MVGxNEDPxE1? MYm0PEBp NUL3PYdETE2VTx?= M4mwd2lv\HWlZYOgZZBweHSxc3nz MWKyOVE2OjJ2NR?=
BON-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO4OVAxKG6P M4LWS|ExKGR? M2DXU2ROW09? NGrXSIdKdmirYnn0d{Bk\WyuIHfyc5d1cA>? M{P5c|I2ODJ4Mkmy
BON-1 NI[5UFdHfW6ldHnvckBCe3OjeR?= NGWwW|I2ODBibl2= M1LhbVQhcA>? NWja[nNHTE2VTx?= MX7Jcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGTodlMxQCCjbnSgV4VzPDd| M3[3PFI2ODJ4Mkmy
QGP-1 M{G4RmZ2dmO2aX;uJGF{e2G7 Mnj6OVAxKG6P NEXaeXg1KGh? M4PzR2ROW09? Mm\TTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= NFTsdYozPTB{NkK5Ni=>
Huh7 MoTuSpVv[3Srb36gRZN{[Xl? MUixJO69VQ>? NYD3cll5OSCq NGLVeY9FVVOR NELjXJRKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHNmejR5NB?= NXjrW4JwOjVyMES0NFM>
BNL NVraNmV6TnWwY4Tpc44hSXO|YYm= M3n3U|Eh|ryP NWDwTJdWOSCq NYDmNG1KTE2VTx?= NXzLWId3UW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKFN4 NHXyfoMzPTByNESwNy=>
MDA-MB-175 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnyNUDPxE1? Mm[xOUBl M1XvZmROW09? MnTJTWM2ODxzIN88US=> NIK5cIczPDh5OUe5Oi=>
MDA-MB-134 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXBNUDPxE1? NFnDOWo2KGR? MWPEUXNQ MlzKTWM2ODxzIN88US=> NFzxXogzPDh5OUe5Oi=>
HCC1500 NEfvPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnsNUDPxE1? NUjpfYtOPSCm NYjTd2U4TE2VTx?= NFX4Z4ZKSzVyPEGg{txO NW\TUW5DOjR6N{m3PVY>
EFM-19 NEe4eoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX2NUDPxE1? MV[1JIQ> M3Tub2ROW09? MkLITWM2ODxzIN88US=> M3m3WFI1QDd7N{m2
ZR-75-30 M1LTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjGXoMyKM7:TR?= MnLjOUBl MofNSG1UVw>? MVrJR|UxRDFizszN NFP6b3YzPDh5OUe5Oi=>
MDA-MB-361 MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXtWnoyKM7:TR?= M{nDclUh\A>? MoLNSG1UVw>? MXLJR|UxRDFizszN MnLwNlQ5Pzl5OU[=
T-47D NIr4c5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOxJO69VQ>? MWC1JIQ> NX3qSXN3TE2VTx?= M3\ldWlEPTB:MTFOwG0> MkW3NlQ5Pzl5OU[=
SK-BR-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfkNUDPxE1? MmrROUBl M1jo[WROW09? M33vRWlEPTB:MTFOwG0> M2TpUlI1QDd7N{m2
UACC-732 MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nVVFEh|ryP NYK1WWVmPSCm NFH3cFlFVVOR NHfK[pZKSzVyPEGg{txO M3nqcVI1QDd7N{m2
BT-474 NF7sW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TGUVEh|ryP MkHwOUBl MVTEUXNQ MWTJR|UxRDFizszN NVzveFhGOjR6N{m3PVY>
HCC202 NVHkWXRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\TZXU6OSEQvF2= M3fZS|Uh\A>? NV\WSHl6TE2VTx?= M4LuUWlEPTB:MTFOwG0> M2T1TVI1QDd7N{m2
MCF7 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVyxJO69VQ>? NGDJOGw2KGR? NXXZW3ZZTE2VTx?= MYHJR|UxRDFizszN NWHlPVgyOjR6N{m3PVY>
MDA-MB-415 NH:5UXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSxJO69VQ>? MnzHOUBl NH;1dnZFVVOR NH;Od|ZKSzVyPEGg{txO NVPqXoduOjR6N{m3PVY>
MDA-MB-453 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDnNo5VOSEQvF2= NW\ZcZJbPSCm NUWxcotUTE2VTx?= MVLJR|UxRDFizszN NUDNTnBtOjR6N{m3PVY>
ZR-75-1 Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne2NUDPxE1? M2n0eVUh\A>? MWfEUXNQ NHHScoNKSzVyPEGg{txO MoHaNlQ5Pzl5OU[=
HCC38 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK4Z5BHOSEQvF2= M4n2N|Uh\A>? NYXNOHVnTE2VTx?= M1zWXGlEPTB:MTFOwG0> NGLiRWEzPDh5OUe5Oi=>
HCC1419 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqxJO69VQ>? NXToVHppPSCm NXW5Z4dCTE2VTx?= M13UWWlEPTB:MTFOwG0> NFrkPIEzPDh5OUe5Oi=>
UACC-812 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOxJO69VQ>? NH\3V2I2KGR? M2\KVWROW09? M3uyW2lEPTB:MTFOwG0> M2PaO|I1QDd7N{m2
HCC1187 M33xU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnwPYsyKM7:TR?= MY[1JIQ> Mn3ISG1UVw>? MonpTWM2ODxzIN88US=> M{nlUlI1QDd7N{m2
KPL-1 NF\DNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DQNlEh|ryP MoDwOUBl M2\2dWROW09? NUnjd|RPUUN3MEyxJO69VQ>? MYmyOFg4QTd7Nh?=
SUM-225 NXvzdmF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[yfVEh|ryP NH24T3k2KGR? NGfDPIVFVVOR NIj0dYRKSzVyPEGg{txO NIDNXYszPDh5OUe5Oi=>
EFM-192A Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjhNUDPxE1? NE\1OGo2KGR? NEm5UopFVVOR NYXjOnJbUUN3MEyxJO69VQ>? M1HHblI1QDd7N{m2
JIMT-1 NVvNOIJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:3NUDPxE1? NFPKNnY2KGR? MUTEUXNQ M13YfmlEPTB:MTFOwG0> MYiyOFg4QTd7Nh?=
HCC1143 MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSxJO69VQ>? NFXFb2I2KGR? NI\afHBFVVOR NG\a[XpKSzVyPEGg{txO M4LOWVI1QDd7N{m2
HCC2218 M1nwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTUNUDPxE1? Mm\KOUBl MVLEUXNQ MlXITWM2ODxzIN88US=> NUnrXFBiOjR6N{m3PVY>
MDA-MB-468 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXexJO69VQ>? Mn3LOUBl NF\lb2tFVVOR NG\qXpZKSzVyPEGg{txO M4HTTlI1QDd7N{m2
BT-20 M4TDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qxOFEh|ryP M4DMe|Uh\A>? MWTEUXNQ NIHEN5BKSzVyPEGg{txO NHe3bVIzPDh5OUe5Oi=>
MDA-MB-435 NXGwVoZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvGWlAyKM7:TR?= NVnLV3BLPSCm NWLBR3JHTE2VTx?= M2O0[WlEPTB:MTFOwG0> M2rLe|I1QDd7N{m2
BT-549 M1LWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHOfZQyKM7:TR?= M{XWc|Uh\A>? MnjBSG1UVw>? MUfJR|UxRDFizszN NUTkOIFtOjR6N{m3PVY>
HCC1806 M1WyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW4NUDPxE1? NVrYR4ZWPSCm M{[we2ROW09? NWfLOXpiUUN3MEyxJO69VQ>? NGfpUWIzPDh5OUe5Oi=>
HCC1937 NXXJcHNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjscWZFOSEQvF2= M{TobVUh\A>? NX7iUJJkTE2VTx?= NULR[4F5UUN3MEyxJO69VQ>? M3\lOVI1QDd7N{m2
Hs578T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rlNlEh|ryP MXy1JIQ> NYGx[3M6TE2VTx?= MWXJR|UxRDFizszN NHzzbFgzPDh5OUe5Oi=>
LN18 NGHleFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O0PFIxKM7:TR?= MVW3NkBp NHLvbVdFVVOR NGjzfGNKSzVyPEWg{txO MXeyOFc1OTB5NB?=
LN229 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NISweIkzOCEQvF2= NXroN4s3PzJiaB?= MWrEUXNQ MnfMTWM2ODx3IN88US=> MnHYNlQ4PDFyN{S=
LNZ308 Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfONlAh|ryP Mn;EO|IhcA>? Mme2SG1UVw>? M{G5eWlEPTB:NTFOwG0> NYXRcVA4OjR5NEGwO|Q>
T98G NUnQdo1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi3eWFXOjBizszN NF3KWFI4OiCq Ml7vSG1UVw>? NHXaOmVKSzVyPEWg{txO MljENlQ4PDFyN{S=
U87 NH\ye2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nPelIxKM7:TR?= M4DRVVczKGh? M2KyNmROW09? NHzmO5JKSzVyPEWg{txO M17mV|I1PzRzMEe0
LN18 MUnGeY5kfGmxbjDBd5NigQ>? MkS5OUDPxE1? NUCzd4JJOjRiaB?= MnzNSG1UVw>? MlzvTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? MWiyOFc1OTB5NB?=
LNZ308 MYLGeY5kfGmxbjDBd5NigQ>? NHvXeGc2KM7:TR?= NXrZR5gxOjRiaB?= NV7ucGJoTE2VTx?= MV7Jcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtV NUDQV|ZnOjR5NEGwO|Q>
Saos-2 MYXGeY5kfGmxbjDBd5NigQ>? M1rkW|UxKM7:TR?= Mm\wOFghcA>? NG[0eFdKdmirYnn0d{Bk\WyuIHnueoF{cW:w Mm\ONlQ4Ojd4NkC=
MG-63 NEi5dHFHfW6ldHnvckBCe3OjeR?= NXnqWGhVPTBizszN Mn7JOFghcA>? M{XtT2lvcGmkaYTzJINmdGxiaX72ZZNqd25? M2L4SlI1PzJ5Nk[w
SJSA-1 M4XXRWZ2dmO2aX;uJGF{e2G7 MVG1NEDPxE1? Ml\COFghcA>? MYjJcohq[mm2czDj[YxtKGmwdnHzbY9v MWCyOFczPzZ4MB?=
Saos-2 M32zVGZ2dmO2aX;uJGF{e2G7 M4XWOVUxKM7:TR?= M1nnSFQ5KGh? NGj4d5ZKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v MkLSNlQ4Ojd4NkC=
MG-63 MUXGeY5kfGmxbjDBd5NigQ>? M4jYO|UxKM7:TR?= M4HtOlQ5KGh? MWrJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO|aX;u M3PyZVI1PzJ5Nk[w
SJSA-1 MnrCSpVv[3Srb36gRZN{[Xl? MVq1NEDPxE1? MkjHOFghcA>? NV70OGFuUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? M2\hSFI1PzJ5Nk[w
Saos-2 NU\LWFB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED6OoM2OCEQvF2= NIjuTlI1QCCq M4HO[GlvcGmkaYTzJINmdGxidnnhZoltcXS7 MYGyOFczPzZ4MB?=
MG-63 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHKS5NOPTBizszN MlTSOFghcA>? NXn2PJV1UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MUWyOFczPzZ4MB?=
SJSA-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXwfXA2OCEQvF2= M1vHflQ5KGh? NW\pSIxZUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NFXYXnozPDd{N{[2NC=>
FaDu MkWzSpVv[3Srb36gRZN{[Xl? MYq1JO69VQ>? NIrlR2YzPCCq MUjEUXNQ M37WfHJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u MmLTNlQ3OzFzNEe=
EMT6 MXXGeY5kfGmxbjDBd5NigQ>? MWe1JO69VQ>? MX2yOEBp MXLEUXNQ M{f5cnJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u MYWyOFY{OTF2Nx?=
HCT116 NWnkNIpkTnWwY4Tpc44hSXO|YYm= M3vaTFUh|ryP MYSyOEBp NWHqeoNvTE2VTx?= NXnhXpFuWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> MnHONlQ3OzFzNEe=
U87 MV3GeY5kfGmxbjDBd5NigQ>? NYr2S5N1PSEQvF2= MmTxNlQhcA>? MoDrSG1UVw>? Mm\KVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= NW\MVWJ4OjR4M{GxOFc>
GBM NUi0TWZTSXCxcITvd4l{KEG|c3H5 NVS1cYpnOs7:TR?= MVK0PIg> MkTiSG1UVw>? MlzKbY5lfWOnZDDobYdp\XJibHX2[Yx{KG:oIHHwc5B1d3OrczygZY5lKGSnY4LlZZNm\CClZXzsJJZq[WKrbHn0fS=> NFv6UpozPDVyMES5Ni=>
BON MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3iw[|EuPc7:TR?= MoT1O|Jp NWTud3Br\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? MmnLNlQ1PDN3MkO=
BON MX3BdI9xfG:|aYOgRZN{[Xl? M4jZd|EuPc7:TR?= NIDPNJozPGh? NG\4VYVqdmO{ZXHz[ZMh[XCxcITvd4l{ NIr6OG0zPDR2M{WyNy=>
H1975 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrwWnUxNjNvOT62{txO MWi3Nog> NY\xeoRYTE2VTx?= NI\jd3RKSzVyPUGuN|g2|ryP NXT5OnlpOjR|M{e4OFY>
H1975 MXHBdI9xfG:|aYOgRZN{[Xl? MnLJNu69VQ>? MXWyOIg> M3fYeWROW09? NYLaXIYycW6lcnXhd4V{KGGyb4D0c5NqeyC{YYTlJJNq\26rZnnjZY51dHl? NYjiO3VrOjR|M{e4OFY>
T-ALL NWnS[|ViSXCxcITvd4l{KEG|c3H5 M1TSWoJmfHenZX6gNU41KGGwZDC1MlMhdU1iYYSgNlRpKGGwZDCwMlkh[W6mIEWuOUBuVSCjdDC0PIghcW5iZHnm[oVz\W62IHPlcIwhdGmwZR?= NUO1V4lJOjRib4KgOFhp NFT2OXZFVVOR MWjh[oZm[3S|IITo[UBRUTONIIDheIh4[XliaX6gWE1CVExiY3XscEBtcW6ncx?= MVqyOFMyODd|Nh?=
BCR-ABL NFznPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17XUVAvOjVvMUFOwG0> MXe0[C=> NF31RWd{cWewaX\pZ4FvfGy7IHnubIljcXRiY3XscEBxem:uaX\ldoF1cW:w MoHHNlQzPDR4MUK=
LC-1/SQSF NYfQZXZMTnWwY4Tpc44hSXO|YYm= NU\D[5lpO87:TR?= NIH5bHMzPGh? NIr0SIZFVVOR MoL4[IVkemWjc3WgUnJHOiCycn;0[YlvKGyndnXs NELKOHAzOzl6MEC5Ny=>
Primary CLL cells NELPSpZCeG:ydH;zbZMhSXO|YYm= MlrQNU0yOM7:TR?= Ml\NOFhp NYqwTFdUcW6mdXPld{BieG:ydH;zbZMhcW5iQ1zMJINmdGy|IHnu[IVx\W6mZX70JI9nKHC{b3fuc5N1cWNibXHyb4Vzew>? NGnNOXczOzh3MEiwOy=>
Primary CLL cells MU\LbY5ie2ViQYPzZZk> MknyNu69VQ>? MU[zNI1qdg>? MkS2[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl? NG\GVHkzOzh3MEiwOy=>
Primary CLL cells MnziR5l1d3SxeHnjJGF{e2G7 MofjNu69VQ>? NYnMW3BPOjSq NYX2dnh3cW6mdXPld{Bk\WyuIHP5eI91d3irY3n0fS=> NVPVT2lZOjN6NUC4NFc>
human NSCLC cell lines MmHFRZBweHSxc3nzJGF{e2G7 MYOwMlEzPS12zszN MmjBNlRp NX[1Vmk2TE2VTx?= M1XrPGlEPTC|IILhcodmeyCocn;tJFAvPC1{zszN M2frO|I{PTZ{NEey
human HCC cell lines NHjJ[2RE\WyuII\pZYJqdGm2eTDhd5NigQ>? MV6wMlAxPS1zzszN Mn7xOFhp MYHJR|UxRTIQvF2= MVKyN|Q5QTl7OR?=
Huh7 NV;BeG1pU2mwYYPlJGF{e2G7 MWqx{txO MYq0PIg> NXXFWIpPe2mpbnpvsKFk[W62bImgdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gRYt1 MmDNNlM1QDl7OUm=
SK-HEP1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDrfnI{OS1{MN88US=> MWm3Nog> MX\EUXNQ MYrJR|Ux97zeMd88US=> MUKyN|Q4QTF|Nh?=
786-0 NVjIfpc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13FTVEuOjEQvF2= NUjmUm1xPzKq MWTEUXNQ Ml7xTWM2OO,:nEJOwG0> Mmq3NlM1PzlzM{[=
JVM2 M2LGOmN6fG:2b4jpZ4l1gSCjc4PhfS=> MWiwMlIuOjEQvF2= MlzBO|Jp MoqzSG1UVw>? Mmf3TWM2OD1yLkpOwG0> NEjP[lczOzJ|OE[zPS=>
EHEB NIX6N5FEgXSxdH;4bYNqfHliYYPzZZk> NITKXmMxNjJvMkFOwG0> NH\Ke3M4Omh? Mo[1SG1UVw>? MmDLTWM2OD1yLkhOwG0> MmnYNlMzOzh4M{m=
MEC2 NYDlXll2S3m2b4TvfIlkcXS7IHHzd4F6 Ml7xNE4zNTJyzszN MoTzO|Jp MlXwSG1UVw>? MnzHTWM2OD1yLkhOwG0> M3TlRVI{OjN6NkO5
primary B-CLL lymphocytes MV;BdI9xfG:|aYOgRZN{[Xl? MUTJR|UxKG[xcjDlZYNpKHC{aX3hdpkh[2WubDDsbY5m NXW0UlVoOjSq M3nnXmROW09? MoTMTWM2OO,:nEROwG0h\m:{IHHscEBx[XSrZX70dy=> Mny0NlMzOzh4M{m=
primary B-CLL lymphocytes NVvoR3FWU2mwYYPlJGF{e2G7 NVLqXJJvUUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?= NHnaXnUzPGh? M4fkeIlvcGmkaYTzJJA4OFN4SzCmJFRGNUKSMTDlfJBz\XO|aX;u NHnafoQzOzJ|OE[zPS=>
human NSCLC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrHNE42NTMQvF2= NUjORZd1PzKq NUjDdFl3UUN3ME2x{txO M4D5OlIzPzhzM{mz
human NSCLC M{jqUGtqdmG|ZTDBd5NigQ>? MkLTNe69VQ>? NGDVToczPGh? NE\IdopqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70 M4XOSVIzPzhzM{mz
Y1 cell line NUTHfnFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rWV|AvOc7:TT:x{txO M{njOFI1cA>? M3z0WWROW09? MVvpcohq[mm2czC2NQ+9jSClZXzsJJZq[WKrbHn0fUBqdiCPeXOtV4N1ei22cnHud4Zm[3SnZDDj[Yxtew>? NVSyPGFsOjJ4OUK5NFQ>
PIK3CA-mutant MCF7 NVrNUVVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\HTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO|NvVQ>? MXS3Nog> MX;HTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO|NvVQ>? NUXVUYl5OjJ4NUO5Olc>
PIK3CA-mutant MCF7 M4nOPGtqdmG|ZTDBd5NigQ>? MVLJR|UxRTFzNNMxN45O NXm3[3ZNPzKq NV36WWdKUUN3ME2xNVTDuTOwTTDpckBz\WS3Y3nu[{BCc3RicHjvd5Bpd3K7bHH0bY9vKGyndnXsdy=> NEjofWMzOjZ3M{m2Oy=>
MCF7-myr-Akt M4CzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnhdmlST0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= NHKySHI4Omh? NYDNToJmT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= NYLST5RsOjJ4NUO5Olc>
colon cancer cell lines MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuwMVEx|ryP NHXadIg4Omh? MVzEUXNQ Mmf0TWM2OD1zzszN MVSyNlU1Ozh3Nx?=
gastric cancer cell lines M3zJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTyclgyOC1zMN88US=> M4DkV|czcA>? NFjyWoNFVVOR MXnJR|UxRTJvNd88US=> MkDZNlI2PDN6NUe=
HCT-116/HT-29/MKN-45 M2DpfGFxd3C2b4Ppd{BCe3OjeR?= NVzpUYo1Os7:TR?= NGDZR481QGh? M3\NXJNpcW[2IHnuJGczKHCqYYPl MWCyNlU1Ozh3Nx?=
HT-29 and HCT-116 MYDDZZNx[XOnIHHzd4F6 NInpVpU2|ryP M2juelI1cA>? NVTzVmV7cW6mdXPld{Bk[XOyYYPlJIFkfGm4aYT5 MXeyNlU1Ozh3Nx?=
MM cell lines Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPhWY4yOM7:TR?= NV3KRmVFOjSq NXTyVnJpTE2VTx?= NXzRZ2pFUUN3MDD2ZZJq\XNiYX3vcoch\GmoZnXy[Y51KGOnbHygcIlv\XNiaX6geIlu\SCjbnSg[I9{\SCmZYDlcoRmdmOn NX;vN3dtOjJ{MEe0PFU>
ARP-1 NE\a[5pCeG:ydH;zbZMhSXO|YYm= NVv1OIpOOTEQvF2= MoPrNlRp M3jsPGROW09? M1q5d4lv\HWlZYOgUW0h[2WubDDhdI9xfG:|aYOgeIhzd3WpaDDjZZNx[XOnIHHjeIl3[XSrb36= NVTXN5J5OjJ{MEe0PFU>
SNU-601 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUm3Nog> NHHqT4ZFVVOR NF;iTVNKSzVyPUCuPFE3yrFyLkC2N:69VQ>? M2TtRVIzOTV7OEG0
SNU-1 NHro[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fQblczcA>? NXXnd3RpTE2VTx?= MmTjTWM2OD1zLkC4NuKyOC5yMklOwG0> NITkb5IzOjF3OUixOC=>
SNU-668 MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXTNVRsPzKq M4fLRWROW09? MU\JR|UxRTFwNUe5xtExNjB5NN88US=> M{\udVIzOTV7OEG0
AGS MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHrO|Jp MmLMSG1UVw>? NFzwUHlKSzVyPUGuO|E1yrFyLkGxO:69VQ>? M3nmcVIzOTV7OEG0
SNU-216 NHnSc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD4O|Jp MoPWSG1UVw>? NHHkbJhKSzVyPUKuOlkzyrFyLkC4Nu69VQ>? NEXsZ3MzOjF3OUixOC=>
SNU-5 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Xxb|czcA>? MWDEUXNQ MWHJR|UxRTFwM{WxxtExNjB7Md88US=> NG\kW5EzOjF3OUixOC=>
SNU-638 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7FNHFHPzKq NGPCVIxFVVOR NFPsd5lKSzVyPUKuNlgzyrFyLkC1N:69VQ>? M4TrTVIzOTV7OEG0
SNU-16 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzvOY5GPzKq M1\ReGROW09? MmPhTWM2OD1zLkW3N:KyOC5yMEJOwG0> MXmyNlE2QThzNB?=
SNU-484 NFPvT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLOO|Jp NWC4R3hUTE2VTx?= NXu0c2xmUUN3ME2xMlczQMLzMD6wOFXPxE1? MmDNNlIyPTl6MUS=
SNU-620 NGDLW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfmSZFDPzKq NUm5SnhsTE2VTx?= MmDnTWM2OD1{LkmzPeKyOC5yMEJOwG0> MVWyNlE2QThzNB?=
SNU-719 MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LMe|czcA>? M4HORmROW09? NGSzPWxKSzVyPUOuNFM4yrFyLkCzNu69VQ>? NX7zRm9nOjJzNUm4NVQ>
glioma cell lines NWO5b|FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe5Um44Omh? MVnJR|UxRTFvMt88US=> MWOyNlA3PTB6MB?=
U87 NWDYNGl3SXCxcITvd4l{KEG|c3H5 M4jRdlLPxE1? MnruO|Jp MUXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGGwZDDjcIVifmWmIGDBVnAh[W6mIHPhd5Bie2VvMx?= Mmn0NlIxPjVyOEC=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT (T308) / p-AKT (S473) / AKT; 

PubMed: 27283525     


Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation.

p-FOXO3a (S253) / FOXO3a; 

PubMed: 28036259     


Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control.

Nuclear NF-κB p65 / NF-κB p65; 

PubMed: 26673665     


Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. 

p-ERK / ERK / LC3; 

PubMed: 27572309     


The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins.

p-STAT3 / STAT3 / p-ERK / ERK / p-S6; 

PubMed: 29928341     


Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h.

p-MET / MET; 

PubMed: 29928341     


The expression of phosphorylated or total forms of MET protein was analyzed by western blotting. 

27283525 28036259 26673665 27572309 29928341
Immunofluorescence
FOXO3a; 

PubMed: 28036259     


Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.

28036259
Growth inhibition assay
Cell viability; 

PubMed: 26673665     


Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).

26673665
体内研究 BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤,完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型,显示抗癌活性。[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型,导致肿瘤体积和K链水平明显降低。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[2]
- 合并

PI3K 生化实验(ATP 消耗实验):

BKM120溶于DMSO中,按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT,及0.05% CHAPS),然后加到每孔中,随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗,然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟,然后通过荧光测定残留的ATP。
细胞实验:[1]
- 合并
  • Cell lines: A2780细 胞
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3天
  • Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔103个细胞的密度接种在相同培养基上,温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中,在37oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠
  • Dosages: ~60 mg/kg
  • Administration: 每天口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.39
化学式

C18H21F3N6O2

CAS号 944396-07-0
储存条件 粉状
溶于溶剂
别名 NVP-BKM120

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04338399 Not yet recruiting Drug: Buparlisib & Paclitaxel Head and Neck Cancer Adlai Nortye Biopharma Co. Ltd. July 31 2020 Phase 3
NCT02614508 Terminated Drug: Buparlisib|Drug: Ibrutinib|Biological: Ofatumumab Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Drug: BKM120 Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Buparlisib (BKM120) | Buparlisib (BKM120)供应商 | 采购Buparlisib (BKM120) | Buparlisib (BKM120)价格 | Buparlisib (BKM120)生产 | 订购Buparlisib (BKM120) | Buparlisib (BKM120)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID